Literature DB >> 31793421

Active Targeting Towards and Inside the Brain based on Nanoparticles: A Review.

Morteza Rabiei1, Soheila Kashanian1,2,3, Seyedeh S Samavati1, Shahriar Jamasb4, Steven J P McInnes5.   

Abstract

BACKGROUND: Treatment of neurological diseases using systemic and non-surgical techniques presents a significant challenge in medicine. This challenge is chiefly associated with the condensation and coherence of the brain tissue.
METHODS: The coherence structure of the brain is due to the presence of the blood-brain barrier (BBB), which consists of a continuous layer of capillary endothelial cells. The BBB prevents most drugs from entering the brain tissue and is highly selective, permitting only metabolic substances and nutrients to pass through.
RESULTS: Although this challenge has caused difficulties for the treatment of neurological diseases, it has opened up a broad research area in the field of drug delivery. Through the utilization of nanoparticles (NPs), nanotechnology can provide the ideal condition for passing through the BBB.
CONCLUSION: NPs with suitable dimensions and optimum hydrophobicity and charge, as well as appropriate functionalization, can accumulate in the brain. Furthermore, NPs can facilitate the targeted delivery of therapeutics into the brain areas involved in Alzheimer's disease, Parkinson's disease, stroke, glioma, migraine, and other neurological disorders. This review describes these methods of actively targeting specific areas of the brain. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Neurological diseases; blood-brain barrier; hydrophobicity; nanoparticles; nanotechnology; targeted delivery.

Mesh:

Substances:

Year:  2020        PMID: 31793421     DOI: 10.2174/1389201020666191203094057

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  2 in total

1.  The cell-permeable mitochondrial calcium uniporter inhibitor Ru265 preserves cortical neuron respiration after lethal oxygen glucose deprivation and reduces hypoxic/ischemic brain injury.

Authors:  Robyn J Novorolsky; Matthew Nichols; Jong S Kim; Evgeny V Pavlov; Joshua J Woods; Justin J Wilson; George S Robertson
Journal:  J Cereb Blood Flow Metab       Date:  2020-03-03       Impact factor: 6.200

Review 2.  Next-Generation Anti-Angiogenic Therapies as a Future Prospect for Glioma Immunotherapy; From Bench to Bedside.

Authors:  Parisa Shamshiripour; Fahimeh Hajiahmadi; Shahla Lotfi; Niloofar Robab Esmaeili; Amir Zare; Mahzad Akbarpour; Davoud Ahmadvand
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.